Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2-E26.2 - How simply "Vertebrate" will future NASH therapy be?
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversatio…
S2-E26.1 - What will NASH Pharmacotherapy Look Like When we have Multiple Options?
Mazen Noureddin returns to discuss the roles different drugs and drug classes will play in NASH therpy after current Phase 2b and Phase 3 candidates have been approved. This conversatio…
S2-E26 - What Will Treatment Pathways Look Like For NASH Patients?
Mazen Noureddin joins the Surfers to explore the issues and needs that will shape treatment guidelines in a world after NASH drugs come to market.
In Season 2 Episode 16, a discussion of…
S2-E25.2 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Deeper Dive
(This episode has been reposted to include the complete conversation content.)
Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof.…
S2-E25.1 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- Key Findings
(This episode has been reposted to include the complete conversation content.)
Stephen Harrison, Naim Alkhouri and first-time guest Prof. Samer Gowrieh share key findings from their 202…
S2-E25.3 (CORRECTED) - Prevalence of NAFLD and NASH 2021 -- An Urgent Call to Action
(This episode has been reposted to include the complete conversation content.)
Louise Campbell and Roger Green join co-authors Stephen Harrison, Naim Alkhouri and first-time guest Prof. …
S2-E25 - How many Americans Are Living with NAFLD and NASH?
Study co-authors Stephen Harrison, Naim Alkhouri and Samer Gawrieh suggest that current estimates of NAFLD and NASH populations in the US may be meaningfully understated.
Earlier this ye…
S2-E24.3 - From The Fourth Global NASH Congress -- How Diagnostics Will Evolve Over The Next Several Years
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This con…
S2-E24.2 - From The Fourth Global NASH Congress -- How Treatment WIll Evolve Over The Next Several Years
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This con…
S2-E24.1 - From the Fourth Global NASH Congress -- Changing Paradigms and Guidelines
After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This con…
S2-E24 - Fourth Global NASH Congress -- Wrapping Up
The SurfingNASH coverage team from the Fourth Global NASH Congress convenes one more time to consider key takeaways from the Congress. Manal Abdelbalek, Naim Alkhouri, Ian Rowe, Suneil …
S2-E23.1 - From the Fourth Global NASH Congress -- Diagnosing Diagnostics
The SurfingNASH Team has curated over three hours of recordings from the Fourth Global NASH Congress to highlight pieces that discuss the current and future states of diagnostics in Fat…
S2-E23 - Wrapping up Day Two of the Fourth Global NASH Congress -- Drugs, lifestyles and Health policy
Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise and Roger as they keep discussing Day Two of the 4th Global NASH Congress.
On April 29, over 175 NASH stakeholder…
S2-E22 - Day Two at the 4th Global NASH Congress -- many New Drugs and Non-Pharmacologic Interventions
Naim Alkhouri, Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise Campbell and Roger Green to review presentations from Day Two at the 4th Global NASH Congress.
On …
S2-E21 - Day One At The 4th Global NASH Congress -- Diagnostics, Drugs And Regulatory Issues
Manal Abdelmalek, Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review presentations from Day One at the 4th Global NASH Congress.
On April 28…
S2-E20.3 - How Can we Best Use NASHmap in Clinical trials and Patient Treatment?
The Surfers explore the impact that NASHmap, the first Machine Learning model that can identify patients likely to have NASH, can have on clinical trials and patient treatment.
Prof. Sch…
S2-E20.2 - What Can We Learn about NASH From NASHmap?
The Surfers analyze outputs from NASHmap, the first Machine Learning model that can identify patients likely to have NASH, to learn what we can about the disease and how to think about …
S2-E20 - 14-variable Machine Learning model identifies Probable NASH patients from Electronic Health Records
Jörn Schattenberg discusses NASHmap, the first Machine Learning model that can identify patients likely to have NASH in clinical settings. Louise, Roger and guest Dr. Kris Kowdley join …
S2-E20.1 - How NASHmap, the 1st Machine Learning Model to Identify Probable NASH Patients, Came to Life
Jörn Schattenberg discusses the issues that drove the project to develop a Machine Learning model that can identify patients likely to have NASH in clinical settings, and discusses key …
S2-E19.3 - Pharmacotherapy Themes At The 4th Global NASH Congress
Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review pharmacotherapy themes to be covered at the 4th Global NASH Congress.
Keynote Speaker Sun…